"10.1371_journal.pone.0058443","plos one","2013-03-08T00:00:00Z","Vered Padler-Karavani; Adriana H Tremoulet; Hai Yu; Xi Chen; Jane C Burns; Ajit Varki","Glycobiology Research and Training Center, Departments of Medicine and Cellular & Molecular Medicine, University of California San Diego, La Jolla, California, United States of America; Department of Pediatrics, University of California San Diego, Rady Children’s Hospital, San Diego, California, United States of America; Department of Chemistry, University of California Davis, Davis, California, United States of America","Read and approved the manuscript: VP-K AHT HY XC JCB AV. Conceived and designed the experiments: VP-K AHT JCB AV. Performed the experiments: VP-K. Analyzed the data: VP-K. Contributed reagents/materials/analysis tools: AHT HY XC JCB. Wrote the paper: VP-K AV.","The authors have read the journal’s policy and have the following conflicts: A.V. is co-founder of and Scientific Advisor to Sialix Inc, a startup biotech company interested in the practical relevance of anti-Neu5Gc antibodies to human disease. The submission is related to US Patent No: 7,682,794 entitled “Methods for detecting and analyzing N-glycolylneuraminic acid (Neu5Gc) in biological materials”. Additional patent applications may be made in relation to the content of the current paper. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","03","Vered Padler-Karavani","VPK",6,TRUE,4,1,1,2,TRUE,TRUE,FALSE,0,NA,FALSE
